A-R Hanauske1, M Lahn2, L C Musib2, K Weigang-Köhler3, E Yilmaz4, T Graefe4, B Kuenen5, D Thornton2, P McNealy2, G Giaccone6. 1. I. Medical Department, General Hospital, St Georg, Hamburg, Germany. 2. Early Phase Clinical Oncology Development, Eli Lilly and Company, Indianapolis, IN, USA. 3. Medical Clinic 5, Oncology and Hematology, Clinic Nürnberg Nord, Nürnberg. 4. I. Medical Department, General Hospital, Hamburg, Germany. 5. Department of Medical Oncology, VU Medical Center, Amsterdam, Netherlands. 6. Department of Medical Oncology, VU Medical Center, Amsterdam, Netherlands. Electronic address: giacconeg@mail.nih.gov.
Abstract
BACKGROUND: This phase Ib study evaluated the safety, pharmacokinetics, and activity of enzastaurin either 500 mg once daily (QD) or 250 mg twice daily (b.i.d.) in combination with pemetrexed. PATIENTS AND METHODS: Pemetrexed 500 mg/m(2) with folic acid and vitamin B(12) was given on day 1 every 21 days with enzastaurin 500 mg orally QD starting on day 5 of cycle 1 after a loading dose of 400 mg thrice daily on day 4. To evaluate whether a b.i.d. regimen results in higher enzastaurin exposures, the study was amended. After amendment, in cycle 1, patients received 500 mg enzastaurin QD on days 1-15 without initial loading dose and 250 mg b.i.d. on days 16-30; in subsequent cycles, patients received pemetrexed on day 1 every 21 days with enzastaurin b.i.d. RESULTS: Sixty-eight patients (42 preamendment and 26 postamendment) were assessed. Pemetrexed toxicity and pharmacokinetics did not appear to be altered by enzastaurin. Enzastaurin average steady-state plasma concentration (C(av,ss)) decreased by approximately 25% in the presence of pemetrexed. Enzastaurin C(av,ss) were approximately 40% higher in the b.i.d. versus QD regimen. Three patients (4.4%) with thyroid cancer of follicular/papillary type had partial response as defined by RECIST. CONCLUSIONS: Pemetrexed plus enzastaurin is well tolerated with preliminary evidence of anticancer activity, particularly in thyroid cancer.
BACKGROUND: This phase Ib study evaluated the safety, pharmacokinetics, and activity of enzastaurin either 500 mg once daily (QD) or 250 mg twice daily (b.i.d.) in combination with pemetrexed. PATIENTS AND METHODS: Pemetrexed 500 mg/m(2) with folic acid and vitamin B(12) was given on day 1 every 21 days with enzastaurin 500 mg orally QD starting on day 5 of cycle 1 after a loading dose of 400 mg thrice daily on day 4. To evaluate whether a b.i.d. regimen results in higher enzastaurin exposures, the study was amended. After amendment, in cycle 1, patients received 500 mg enzastaurin QD on days 1-15 without initial loading dose and 250 mg b.i.d. on days 16-30; in subsequent cycles, patients received pemetrexed on day 1 every 21 days with enzastaurin b.i.d. RESULTS: Sixty-eight patients (42 preamendment and 26 postamendment) were assessed. Pemetrexedtoxicity and pharmacokinetics did not appear to be altered by enzastaurin. Enzastaurin average steady-state plasma concentration (C(av,ss)) decreased by approximately 25% in the presence of pemetrexed. Enzastaurin C(av,ss) were approximately 40% higher in the b.i.d. versus QD regimen. Three patients (4.4%) with thyroid cancer of follicular/papillary type had partial response as defined by RECIST. CONCLUSIONS:Pemetrexed plus enzastaurin is well tolerated with preliminary evidence of anticancer activity, particularly in thyroid cancer.
Authors: Peter P Ruvolo; Liran Zhou; Julie C Watt; Vivian R Ruvolo; Jared K Burks; Tilahun Jiffar; Steven Kornblau; Marina Konopleva; Michael Andreeff Journal: J Cell Biochem Date: 2011-06 Impact factor: 4.429
Authors: Lindsay B Kilburn; Mehmet Kocak; Rodney L Decker; Cynthia Wetmore; Murali Chintagumpala; Jack Su; Stewart Goldman; Anuradha Banerjee; Richard Gilbertson; Maryam Fouladi; Larry Kun; James M Boyett; Susan M Blaney Journal: Neuro Oncol Date: 2014-11-27 Impact factor: 12.300
Authors: Glen J Weiss; Ross C Donehower; Tara Iyengar; Ramesh K Ramanathan; Karen Lewandowski; Eric Westin; Karla Hurt; Scott M Hynes; Stephen P Anthony; Scott McKane Journal: Invest New Drugs Date: 2012-04-11 Impact factor: 3.850
Authors: Nwabundo Nwankwo; Zhe Zhang; Ting Wang; Connie Collins; Lee Resta; Sabine Ermisch; Jeannette Day; Rodney Decker; Lori Kornberg; Steven Nicol; Donald Thornton; Deborah K Armstrong; Michael A Carducci Journal: Invest New Drugs Date: 2012-07-06 Impact factor: 3.850
Authors: Sukhmani K Padda; Yelena Krupitskaya; Laveena Chhatwani; George A Fisher; Alexander D Colevas; Melanie San Pedro-Salcedo; Rodney Decker; Jane E Latz; Heather A Wakelee Journal: Cancer Chemother Pharmacol Date: 2011-12-11 Impact factor: 3.333